Stockwinners Market Radar for February 11, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:01 EST Hawaiian Electric raises quarterly dividend to 35c from 34c per share - Payable March 10 to shareholders of record at the close of business on February 24.

17:40 EST Raytheon says it is a target of DOJ hiring practices probe - In a regulatory filing, Raytheon said it received a grand jury subpoena in late 2019, as part of a DOJ criminal investigation into purported agreements not to solicit or hire employees in violation of the federal antitrust laws. While the investigation has focused on alleged hiring restrictions between and among Pratt & Whitney and certain of its suppliers of outsourced engineering services, the subpoena also included requests regarding Collins Aerospace. Since receipt of the subpoena, the company has been cooperating with the DOJ investigation. On December 15, 2021, a criminal indictment was filed in the United States District Court for the District of Connecticut, against a former Pratt & Whitney employee and other employees of certain outsourced engineering suppliers charging each of them with one count of violating the federal antitrust laws. No current or former Collins Aerospace employees were named in the indictment. "We were recently advised that the Company is a target of the DOJ investigation, and we continue to cooperate with the investigation," Raytheon said in the filing. "No criminal charge has been filed against the Company or its affiliates. After the criminal charges against the individuals were filed, numerous civil class action antitrust lawsuits have been filed against Pratt & Whitney and other corporate and individual defendants in the United States District Court for the District of Connecticut. The allegations in each of the civil lawsuits track the factual assertions in the criminal indictment and generally allege that Pratt & Whitney and the other defendants agreed to restrict the hiring and recruiting of certain engineers and skilled laborers in a manner that violated federal antitrust laws. Plaintiffs in each of the civil lawsuits seek to represent different purported classes of engineers and skilled laborers employed by Pratt & Whitney and other supplier-defendants since 2011. Collins Aerospace was also named as a defendant in some of the lawsuits. Plaintiffs in each of the lawsuits seek treble damages in an undetermined amount, plus attorneys' fees and costs of suit. We expect that all the lawsuits ultimately will be consolidated into a single joint complaint. We believe that each of these lawsuits lacks merit. Based on the information available to date, we do not believe that this matter will have a material adverse effect on our results of operations, financial condition or liquidity."

17:26 EST L3Harris Technologies receives $297.2M Special Operations Command modification - L3Harris Technologies received a modification in the amount of $297.2M on indefinite-delivery/indefinite-quantity contract to allow for the continued purchase of the Special Operations Forces Tactical Communications Next Generation Manpack, AN/PRC 167 radios and ancillary equipment. This modification increases the maximum contract ceiling value from $255M, to $552.2M No funds are being obligated via this modification. The majority of the work will be performed in Rochester, New York. This contract modification was awarded through other than full and open competition under 10 U.S. Code 2304. U.S. Special Operations Command Headquarters is the contracting activity.

17:24 EST AstraZeneca awarded $855M Army contract modification - AstraZeneca was awarded an $855M modification to contract for the manufacture, distribution and storage of AZD7442, known as Evusheld, to treat COVID-19 in the general population. Work will be performed in various locations, with an estimated completion date of March 31, 2023. Health and Human Services Biomedical Advanced Research and Development Authority, or HHS BARDA, Coronavirus Aid, Relief and Economics Security Act funds in the amount of $405.3M and HHS BARDA American Rescue Plan Act funds in the amount of $449.7M, were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:07 EST Copa Holdings reports preliminary January traffic statistics - Copa Holdings released preliminary passenger traffic statistics for January. Consolidated capacity, or ASMs, came in 18% lower than January 2019, while passenger traffic, or RPMs, decreased 22%, which resulted in a 79% load factor.

17:01 EST Vinci Partners Infrastructure announces partnership with Aguas do Brasil - Vinci Partners Investments announced the partnership between Vinci Partners' Infrastructure strategy and consortium Aguas do Brasil, establishing a new concessionaire to invest in the public concession of Companhia Estadual de Aguas e Esgotos' Block 3. The company will be ahead of CEDAE's concession of Block 3, won by Aguas do Brasil in the international public bid conducted by the State of Rio de Janeiro, and will be responsible for the provision of water supply and sanitation services for 21 cities in the state. This is the first investment from Vinci Infrastructure Water and Sewage strategy, through a 40% stake held in the company. With this investment, the Fund will reach over 90% deployment considering raised commitments since its first close in 2021.

16:31 EST Vulcan Materials raises quarterly dividend to 40c from 37c per share - The dividend will be payable on March 14 to shareholders of record at the close of business on March 1.

16:20 EST Momentive says ISS recommends holders vote in favor of Zendesk deal - Momentive Global (MNTV) announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. has recommended that Momentive stockholders vote "FOR" the company's previously announced transaction with Zendesk, Inc. (ZEN) at the upcoming Special Meeting of Stockholders. Momentive issued the following statement in response to the report: "We are pleased that ISS supports our Board's unanimous recommendation to vote "FOR" the transaction with Zendesk. The recommendation from ISS recognizes the thorough and robust process led by our highly qualified, independent Board of Directors, as well as our commitment to identifying opportunities that maximize stockholder value. Customer intelligence has never been more important, and combining with Zendesk is the next natural step for Momentive. We look forward to working to complete our transaction with Zendesk and unlocking value for our customers and stockholders."

16:17 EST CapStar Financial CFO Michael Fowler resumes role, Amy Goodin named CRO - CapStar Financial announced the following appointments to its executive management team. Michael Fowler resumed his role as executive VP, CFO effective February 11 after stepping down to treasurer in the fall of 2020 to provide care for his spouse during her 18-month battle with cancer. He replaces Denis Duncan, who served as CFO during this period, and retired effective February 10. Amy Goodin has been appointed chief risk officer, or CRO, and corporate secretary overseeing legal, regulatory relations, insurance, internal audit, vendor management, compliance, and information security. Goodin joined the company in 2000 and oversaw human resources, compliance, and internal audit at Athens Federal Community Bank which was acquired by CapStar in 2018

16:09 EST Novus Capital Corporation II, Energy Vault complete business combination - Novus Capital Corporation II (NXU)announced the completion of its business combination with Energy Vault (NRGV), the company developing sustainable, grid-scale energy storage solutions. In connection with the completion of the business combination, Novus has been renamed Energy Vault Holdings and its common stock and warrants are expected to commence trading on the New York Stock Exchange on Monday, February 14, under the ticker symbols "NRGV" and "NRGV WS" respectively.

15:54 EST Vistas Media Acquisition Company Inc trading resumes

15:39 EST Vistas Media Acquisition Company Inc trading halted, volatility trading pause

15:24 EST Exxon Mobil reports start of production at Guyana's second offshore development - ExxonMobil (XOM) said it started production at Guyana's second offshore oil development on the Stabroek Block, Liza Phase 2, "bringing total production capacity to more than 340,000 barrels per day in only seven years since the country's first discovery." Production at the Liza Unity floating, production, storage and offloading vessel is expected to reach its target of 220,000 barrels of oil later this year, the company said. The current resource has the potential to support up to 10 projects. ExxonMobil anticipates that four FPSOs with a capacity of more than 800,000 barrels per day will be in operation on the Stabroek Block by year-end 2025. ExxonMobil affiliate Esso Exploration and Production Guyana Limited is operator and holds 45% interest. Hess Guyana Exploration Ltd. (HES) holds 30% interest and CNOOC Petroleum Guyana Limited holds 25% interest.

15:11 EST Eli Lilly confirms bebtelovimab granted Emergency Use Authorization for COVID-19 - The U.S. Food and Drug Administration has issued an Emergency Use Authorization for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly announced. Bebtelovimab can now be used for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older weighing at least 40 kg with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate. The authorized dose of bebtelovimab is 175 mg given as an intravenous injection over at least 30 seconds. As previously announced, Lilly has signed an agreement with the U.S. government to supply up to 600,000 doses of investigational drug bebtelovimab for at least $720M, the company noted.

14:44 EST Defense contractors higher after White House says Russia may invade Ukraine soon - Shares of several publicly traded companies in the defense contracting space, including BAE Systems (BAESY), General Dynamics (GD), Lockheed Martin (LMT), and Northrop Grumman (NOC), are advancing in a broadly lower market after White House representatives said earlier at a news briefing that Russia had increased its military at the Ukraine boarder and that an invasion could happen during the Olympics.

14:30 EST Activision says next 'Call of Duty' to be sequel to 2019's 'Modern Warfare' - Activision Blizzard (ATVI), which agreed recently to be acquired by Microsoft (MSFT), said in a blog post that this year's "Call of Duty" is a sequel to 2019's "Call of Duty: Modern Warfare." The company said the new game and a new "Warzone" experience are designed together from the ground-up, and that players should expect a "massive evolution" of Battle Royale with all-new playspace and a new sandbox mode. Activision also noted that a new engine will power both the new "Call of Duty" release and "Warzone," and that development of both games is being led by Infinity Ward. Reference Link

14:06 EST Team trading resumes

13:53 EST PlayStation's Hulst says 'Horizon Zero Dawn' has sold over 20M copies - PlayStation studios head Hermen Hulst said via Twitter that Sony-published game "Horizon Zero Dawn" has sold over 20M copies worldwide across PlayStation 4 and PC. Hulst, who called the game an "incredible achievement" from developer Guerrilla Games, tweeted out the information ahead of the release of sequel "Horizon Forbidden West" for PS4 and PS5 on February 18, 2022. The Fly notes that the PS4 version of "Zero Dawn" released in February 2017, while the PC port became available in August 2020. Reference Link

13:34 EST Pfizer, BioNTech to extend rolling submission for EUA of COVID-19 vaccine - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced plans to extend their rolling submission to the U.S. Food and Drug Administration seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to include children 6 months through 4 years of age, which had been requested by FDA. The trial in children 6 months through 4 years of age is ongoing and data on the first two 3 microgram doses in this age group are being shared with the FDA on an ongoing basis. Cases continue to accumulate according to the study protocol and more data are being generated because rates of infection and illness remain high in children of this age, especially due to the recent Omicron surge. In December 2021, Pfizer and BioNTech announced that the ongoing clinical study would evaluate a third 3 microgram dose at least two months after the second dose of the two-dose series in this age group. Given that the study is advancing at a rapid pace, the companies will wait for the three-dose data as Pfizer and BioNTech continue to believe it may provide a higher level of protection in this age group. This is also supported by recent observations of three dose booster data in several other age groups that seems to meaningfully augment neutralizing antibody levels and real world vaccine protection for omicron compared to the two-dose regimen. The companies expect to have three-dose protection data available in early April. The independent Data Monitoring Committee for the study supports the continuation of the trial according to the protocol and believe that the data collected to date indicate the vaccine is well tolerated and support a potential three-dose regimen. The extension allows the FDA time to receive updated data on the two and three-dose regimen, conduct a thorough evaluation of it and facilitate a robust, public discussion.

13:02 EST Baker Hughes reports U.S. rig count up 22 to 635 rigs - Baker Hughes reports that the U.S. rig count is up 22 from last week to 635 with oil rigs up 19 to 516, gas up 2 to 118, and miscellaneous rigs up 1 to 1. The U.S. Rig Count is up 238 rigs from last year's count of 397 with oil rigs up 210 gas rigs up 28 and miscellaneous unchanged at 1. The U.S. Offshore Rig Count is unchanged at 16, down 1 year-over-year. The Canada Rig Count is up 1 from last week to 219, with oil rigs up 1 to 137, gas rigs unchanged at 82. The Canada Rig Count is up 43 rigs from last year's count of 176, with oil rigs up 36, gas rigs up 7.

13:02 EST Baker Hughes reports U.S. rig count up 22 to 635 rigs

12:57 EST Gundlach says 'never been long or short crypto,' too volatile for him - Jeffrey Gundlach of DoubleLine is speaking on CNBC.

12:55 EST Gundlach sees 'stability' in near-term for U.S. equities - Jeffrey Gundlach of DoubleLine is speaking on CNBC.

12:50 EST Roche announces Actemra/RoActemra granted WHO prequalification for severe COVID - Roche announced that Actemra/RoActemra intravenous has been granted World Health Organization, or WHO, prequalification. "Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. It helps procurers in low- and middle-income countries identify priority medicines to improve access to care and support better health," the company stated. Actemra/RoActemra and Ronapreve, known as REGEN-COV in the United States, were recommended in WHO's Therapeutics and COVID-19 Living Guideline last year, Roche noted.

12:42 EST Gundlach says inflation likely to print 5% for 2022 - Jeffrey Gundlach of DoubleLine is speaking on CNBC.

12:41 EST Gundlach says commodity easing will be replaced by wage growth - Jeffrey Gundlach of DoubleLine is speaking on CNBC.

12:26 EST Spire Global awarded $8M NOAA contract to deliver satellite weather data - Spire Global announced that it has been awarded as part of Indefinite Delivery Indefinite Quantity Delivery Order 4 of the contract issued by the National Oceanographic and Oceanic Administration, for commercially available space-based radio occultation data for use in operational weather forecasts. The award, valued at over $8M, represents the single largest U.S. government purchase of commercial, operational RO data. The award is the next milestone in NOAA's goal to expand the purchase of commercial RO data. It is an increase in the number of RO profiles that Spire provides NOAA from 3,000 to 5,500, serving as a testament to Spire's proven ability to reliably deliver valuable, operational RO data, profiling atmospheric temperatures and related quantities for weather models helping NOAA and as a result American citizens prepare for extreme weather events. In addition to the forecast accuracy benefits, NOAA recently announced commercially sourced data was about one-quarter to one-half the cost of government-sponsored missions, further demonstrating the long-term viability of partnering with Spire. Spire's constellation of more than 100 satellites collects more RO profiles than any other organization across the globe. Spire's data provided to NOAA will be made available in near-real-time to national and international meteorological organizations and the broader U.S. federal government upon receipt, enabling increased information sharing for critical weather data. The data delivery will commence on March 16, 2022 and run until January 18, 2023.

12:08 EST Spire Global trading halted, news pending

12:02 EST Dominion agrees to sell West Virginia natural gas utility to Ullico for $690M - Dominion Energy announced that it has executed a definitive agreement to sell its West Virginia natural gas utility - Hope Gas, Inc. - to Ullico Inc.'s infrastructure fund for $690M. The transaction is expected to close late this year. Ullico Inc.'s infrastructure business plans to integrate DEWV with Hearthstone Utilities, a portfolio company that owns and operates gas utilities in Indiana, Maine, Montana, North Carolina, and Ohio, serving more than 80,000 customers. As part of the definitive agreement, Hearthstone will move its headquarters to West Virginia. DEWV is a Clarksburg, W.Va.-based gas utility employing about 300 and serving 111,000 West Virginia customers, with 3,200 miles of gas distribution pipelines and more than 2,000 miles of gathering pipelines. Dominion Energy continues to own and operate Mt. Storm Power Station in Mt. Storm, W.Va. The sale is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Act and approval from the Public Service Commission of West Virginia.

12:01 EST Mesabi Trust falls -28.1% - Mesabi Trust is down -28.1%, or -$8.60 to $22.01.

12:01 EST Proto Labs rises 12.7% - Proto Labs is up 12.7%, or $6.78 to $60.27.

12:00 EST Carpenter Technology rises 15.6% - Carpenter Technology is up 15.6%, or $5.19 to $38.38.

11:34 EST January U.S. video game spending fell 2% y/y, says NPD - NPD analyst Mat Piscatella said that January 2022 consumer spending across video game hardware, content and accessories in the U.S. declined 2% when compared to a year ago, to $4.7B. A double-digit percentage gain in hardware spending could not offset declines in content and accessories spending. Despite hardware sales gains in January, supply constraints continue to impact video game hardware across all current generation platforms. Total market spending has now shown year-on-year declines for 3 consecutive months. Video game hardware dollar sales increased 22% when compared to January 2021, reaching $390M. This is the highest total for a January month since the $447M total reached in January 2009. Sony's (SONY) PlayStation 5 was the best-selling hardware platform of January 2022 in both units and dollars. Microsoft's (MSFT) Xbox Series ranked 2nd across both measures. The Fly notes that Nintendo's (NTDOY) Switch is also a major game console competitor. Reference Link

10:44 EST Toyota announces added $90M investment in EVs at two U.S. plants - Toyota announced an additional $90M investment for two of its U.S. manufacturing facilities, including $73M at Toyota West Virginia and $17M at Toyota Tennessee. "Toyota is moving quickly toward an electrified future, and West Virginia will play a critical role in that journey. Our team embraces this challenge, and it's clear Toyota has faith in our ability and trusts us to take the company to new heights," said David Rosier, president of TMMWV. "Toyota Tennessee is proud to play an important role in our company's mission to provide customers with safer, reliable, electrified vehicles that advance a carbon-neutral future. Our highly skilled team is excited to expand production of the hybrid transaxle cases and housings," said Wes Woods, president of TMMTN. Reference Link

10:35 EST Cleveland-Cliffs: Scope 3 emissions not yet a 'topic of concern'

10:06 EST Malvern Bancorp appoints Sandra Selzer as EVP, general counsel - Malvern Bancorp announced the appointment of Sandra Selzer as Executive Vice President, General Counsel. In this role, Sandra will be overseeing the legal function of the Company and the Bank. Sandra has nearly two decades of experience as a corporate attorney, most recently serving as Associate In-house Counsel for developer Phoenix RHCS, LLC. in Wilmington, DE.

10:01 EST Malvern Bancorp appoints Sandra Selzer as EVP, general counsel - Malvern Bancorp announced the appointment of Sandra Selzer as Executive Vice President, General Counsel. In this role, Sandra will be overseeing the legal function of the Company and the Bank. Sandra has nearly two decades of experience as a corporate attorney, most recently serving as Associate In-house Counsel for developer Phoenix RHCS, LLC. in Wilmington, DE.

10:00 EST IAA falls -16.5% - IAA is down -16.5%, or -$7.58 to $38.24.

10:00 EST Proto Labs rises 9.3% - Proto Labs is up 9.3%, or $4.96 to $58.45.

10:00 EST Carpenter Technology rises 12.4% - Carpenter Technology is up 12.4%, or $4.10 to $37.29.

09:49 EST US Foods separating roles of CEO and chair

09:47 EST Insperity falls -11.5% - Insperity is down -11.5%, or -$12.46 to $95.94.

09:47 EST Universal Insurance falls -19.3% - Universal Insurance is down -19.3%, or -$3.31 to $13.79.

09:47 EST GoDaddy rises 9.5% - GoDaddy is up 9.5%, or $7.06 to $81.27.

09:46 EST SANG Stock trading resumes

09:42 EST IAA Inc trading resumes

09:39 EST Goodyear Tire sees 2022 cash flow 'around breakeven,' says CFO - Comments taken from Q4 earnings conference call.

09:34 EST Avantor starts construction on new distribution center in Ireland - Avantor has started construction on a distribution center which will help expedite access to essential production materials for biopharmaceutical manufacturers in Ireland. Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry. The more than 68,800 square foot distribution facility will be Avantor's second in Dublin, adding capacity while streamlining processes. The center will feature capabilities such as warehousing of cGMP certified products, batch-to-batch traceability, and customized palletization. On-site clean rooms will also enable customers to conduct raw material sampling to expedite quality inspection and material receipt.

09:31 EST Biosyent adopts Advance Notice By-law - BioSyent announces that its Board of Directors has approved the adoption of an Advance Notice By-law for the purposes of: facilitating an orderly and efficient annual general or, where the need arises, special meeting process; ensuring that all shareholders of the Company receive adequate notice of nominations for the Board of Directors of the Company and sufficient information regarding all director nominees; and allowing shareholders to register an informed vote after having been afforded reasonable time for appropriate deliberation. The By-law establishes a framework for providing advance notice to BioSyent in circumstances where nominations of persons for election to the Board of Directors are made by shareholders of BioSyent. The By-law fixes deadlines by which shareholders of record of BioSyent must submit director nominations to BioSyent prior to any annual or special meeting of shareholders and sets forth the information a shareholder must include in the notice to BioSyent for an effective nomination to occur. No person will be eligible for election as a director of BioSyent unless nominated in accordance with the provisions of the By-law. In the case of an annual meeting of shareholders, the deadline for notice to BioSyent pursuant to the By-law is not less than 30 days prior to the date of the annual meeting of shareholders; provided, however, that: if an annual meeting is called for a date that is less than 50 days after the date on which the first public announcement of the date of the annual meeting was made, notice must be received by BioSyent not later than the close of business on the 10th day following such public announcement; and if the Corporation uses "notice-and-access" to send proxy-related materials to shareholders in connection with an annual meeting, notice must be received by BioSyent not less than 40 days before the date of the annual meeting. In the case of a special meeting of shareholders called for the purpose of electing directors, the deadline for notice to BioSyent pursuant to the By-law is no later than the close of business on the 15th day following the day on which the first public announcement of the date of the special meeting was made. The By-law is effective immediately and will be placed before shareholders for approval, confirmation and ratification at the Company's next annual general and special meeting of shareholders. According to the provisions of the Canada Business Corporations Act, the By-law will cease to be effective unless it is approved, confirmed, and ratified by a resolution adopted by a majority of the shareholder votes cast, in person or by proxy, at the Meeting.

09:29 EST Vaxxinity announces results from studies of UB-612 - Vaxxinity announced results from studies demonstrating the ability of UB-612, its COVID-19 vaccine candidate, to elicit a broad immune response against multiple variants of concern, and specifically more than three-times higher titers of neutralizing antibodies against the Omicron variant of SARS-CoV-2 than an approved mRNA vaccine with boosters. The studies were conducted by David Goldblatt, M.B. Ch.B., Ph.D., at University College London and VisMederi, a Coalition for Epidemic Preparedness Innovations-centralized laboratory. Sera from 92 participants from UB-612's Phase 2 study including 8 placebos and up to 36 participants in the Phase 1 study, half of the latter boosted with a third dose of UB-612, were used in these studies to analyze binding of IgG and neutralization against multiple Variants of Concern and Variants of Interest, including Omicron. Key results from the studies include: Three doses of UB-612 elicited neutralizing antibody titers of GMT VNT50 of 335 against the Omicron variant of SARS-CoV-2, over 3-fold higher than reported after three doses of an approved mRNA vaccine. The receptor-binding domain- and spike protein-binding IgG antibodies after booster immunization with UB-612 produced high cross-reactivity against multiple SARS-CoV-2 variants, including Alpha, Beta, Delta, Gamma and Omicron, similar to or higher than those of approved vaccines and boosters. The RBD-binding antibodies against the Wuhan strain reported for several authorized vaccines are predictive of UB-612 vaccine efficacy against COVID-19 at approximately 95% after three doses. Vaxxinity plans to publish these data and present the findings at World Vaccine Congress in April 2022. UB-612 has been evaluated in Phase 1 and Phase 2 studies and is preparing to launch a global pivotal booster study later this year.

09:17 EST Terreno Realty acquires industrial property in Florida for $73.2M - Terreno Realty acquired an industrial property in Hialeah, Florida on February 9 for a purchase price of approximately $73.2M, net of free-rent credits. The property consists of two recently developed rear-load 32-foot clear industrial distribution buildings containing approximately 407,000 square feet on 19.8 acres. The property is at 4281-4341 West 108th Street, immediately adjacent to Terreno Realty Corporation's five existing buildings on West 108th Street and adjacent to Florida's Turnpike and the southern terminus of I-75. The property provides 124 dock-high and four grade-level loading positions and parking for 359 cars and is expected to obtain LEED certification. The property is 100% pre-leased to two tenants with leases expected to commence in May and September. The estimated stabilized cap rate of the property is 3.8%. Estimated stabilized cap rates are calculated as annualized cash basis net operating income stabilized to market occupancy divided by total acquisition cost. Total acquisition cost includes the initial purchase price, the effects of marking assumed debt to market, buyer's due diligence and closing costs, estimated near-term capital expenditures and leasing costs necessary to achieve stabilization.

09:12 EST Mawson Infrastructure appoints Heath Donald as chief marketing officer - Mawson Infrastructure announced the appointment of Heath Donald as chief marketing officer, or CMO, and Tom Hughes as general counsel. Hughes has over 15 years' legal experience and was most recently head of group legal at HUB24, an ASX200 technology and financial services company, where he was instrumental in building the legal, risk and compliance function. Tom's career includes inhouse legal and secretariat experience across several large publicly listed companies and he has practiced as a senior lawyer at top tier and large corporate law firms, including Clayton Utz. Heath has over 20 years' experience across technology, communications and marketing, primarily in the telecommunications and IT industries. Heath was previously founder and CEO of No Names Digital, a digital marketing business focused on social content marketing and omni-channel sales.

09:04 EST O2Micro announces patent granted for system, methods for driving a battery pack - O2Micro International announced the grant of a patent issued to O2Micro for system and methods for managing a battery pack. O2Micro was issued 17 claims under China Patent No. ZL201910054748.2 on Mar 16, 2021, for the invention of system and methods for managing a battery pack. A battery controller includes a first driving pin, a second driving pin and a third driving pin. The first driving pin is coupled to a charge switch and is operable for turning on the charge switch to enable a battery pack to be charged by a power source. The second driving pin is coupled to a first discharge switch and is operable for turning on the first discharge switch to enable the battery pack to power a first load. The third driving pin is coupled to a second discharge switch and is operable for turning on the second discharge switch to enable the battery pack to power a second load. Dr. Guoxing Li, VP of Advanced Technology, O2Micro, commented, "This invention provides an effective solution for the battery pack management with more than one load while at the same time delivering advanced safety protections."

09:03 EST Liquid Media signs definitive agreement to acquire Digital Cinema - Liquid Media announced that further to its press release dated August 4, 2021, it has executed a definitive agreement to acquire Digital Cinema United Holdings. The closing is expected to be completed in the coming weeks as the remaining customary closing conditions are fulfilled. "With the acquisition of DCU, Liquid inherits DCU's longstanding position as a company of choice for the entertainment and media industry. The services DCU provides are essential to film and TV producers and distributors, engage with clients across every aspect of the supply chain, supercharge our solution engine and further our reach," says Ron Thomson, CEO of Liquid Media. "This transaction is a strategic win for both companies, with DCU bringing a range of loyal clientele, revenue base and stellar reputation worldwide. Liquid brings DCU additional capital that drives rapid growth, back office support to scale execution across verticals, and the benefits of the many arms of its growing family of companies." Under the terms of the definitive agreement, Liquid will acquire DCU for $11.25M payable in common shares of Liquid, which are scheduled to be paid out to DCU investors across specific performance milestones in three tranches. The first tranche of consideration shares is payable on closing and will consist of $3.75M in common shares of Liquid at a price per share of the greater of $1.25 or the five-day Volume Weighted Average Price of Liquid common shares immediately prior to closing. The two remaining milestones will be triggered by DCU generating revenues totaling more than $15M over a period of up to five years.

09:02 EST Senmiao Technology reports January completed orders down 10.9% vs. December - Senmiao Technology reported operating metrics for its proprietary online ride-hailing platform for January 2022. In January 2022, Senmiao reported over 0.9 million total completed orders, a 10.9% decrease from approximately 1.1 million total orders completed in December 2021, as a result of pandemic-related travel restrictions that impacted tourism in Senmiao's key cities. Seasonality driven by the Lunar New Year holiday in China was also behind the decrease. The number of completed rides decreased in the weeks before and after the national holiday on February 1, 2022, which is expected to also impact the number of completed orders in February 2022. The number of drivers completing rides via the platform, known as Active Drivers, in January 2022 was 7,085, a decrease of approximately 10% from that of December 2021.

08:57 EST Under Armour says significant progress in long term growth drivers - Says "excellent progress" in gross margins on two-year basis. Sees stronger brand momentum in years ahead. Says "investing more smartly" in marketing. Expects supply constraints to continue "well into FY23." Sees "material impacts" on results. Comments taken from Q4 earnings conference call.

08:41 EST Nevro's back pain therapy demonstrates effiacy in published 12-month study - Nevro announced 12-month data from the SENZA-NSRBP randomized controlled trial was published online in Journal of Neurosurgery: Spine. These data show that high-frequency 10 kHz spinal cord stimulation - SCS - therapy results in profound improvement in non-surgical refractory back pain - NSRBP - patients compared to Conventional Medical Management. The study compares Nevro's proprietary high-frequency SCS plus CMM to CMM alone in 159 randomized patients. Published 12-month data show sustained effectiveness of 10 kHz Therapy. 12-month NSRBP trial results demonstrate durable pain relief achieved with 10 kHz Therapy. The 12-month data demonstrated these benefits of 10 kHz Therapy: durable pain relief, consistent safety, functional improvement, opioid usage decline. Data from the SENZA-NSRBP trial formed the basis of the company's recent FDA approval for NSRBP.

08:33 EST F45 Training increases purchase of equipment packs, cites growth - F45 Training announced that the company has increased its purchase of equipment packs to support expected significant global franchisee demand. As a result, the company will have approximately 1,200 equipment world packs secured for delivery during 2022, including world packs received year to date.

08:13 EST Immutep granted Australian patent for eftilagimod alpha - Immutep announces the grant of a new patent entitled "Combined Preparations for the Treatment of Cancer or Infection" by the Australian Patent Office. This new Australian patent follows the grant of the corresponding European, United States and Chinese patents announced in 2018 through 2021. The claims of the new patent protect Immutep's intellectual property relating to combined therapeutic preparations comprising (a) its lead active immunotherapy candidate eftilagimod alpha, which is a LAG-3 fusion protein, and (b) an anti-PD-1 or anti-PD-L1 antibody. In addition to broader style claims, the granted claims include narrower claims drawn to specific combinations of efti with pembrolizumab, nivolumab, avelumab, durvalumab or atezolizumab, for example. The claims are also directed to related methods of use in the treatment of cancer. The patent expiry date is 8 January 2036. Immutep CEO, Marc Voigt, noted: "We continue to make progress in protecting efti, which is a unique biomolecule. The LAG-3 / MHC class II immune control mechanism has attracted significant interest from the medical and investment communities in recent weeks following publication of Phase III clinical data by the pharma industry in a very prestigious peer-reviewed medical journal. With our exclusive focus on this mechanism and four candidates under development, we continue to be well placed to make an important contribution to this exciting field. 2022 promises to be a productive year."

08:11 EST Goodyear Tire jumps 5% to $22.81 after Q4 results beat estimates

08:09 EST Fulcrum Therapeutics reports inducement grants under Nasdaq listing rule - Fulcrum Therapeutics announced the grant of inducement awards outside of the Company's 2019 Stock Incentive Plan to Amy Winnen, the Company's newly appointed Vice President, Head of Market Value, Access and Policy. The grant was approved by a majority of the independent directors of the Company on February 3, 2022 as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant consisted of a nonstatutory option to purchase up to 43,260 shares of common stock. The option has an exercise price of $10.93 per share, the closing price per share of the Company's common stock as reported by Nasdaq on February 7, 2022. The option has a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to such employee's continued service with the Company through the applicable vesting dates.

08:09 EST Republic First Bancorp continues to review filings by Shareholder Group - The Board of Directors issued the following statement in response to recent Schedule 13D filings of a shareholder group with the Securities and Exchange Commission: "The Board is committed to discharging its fiduciary duty to the Bank, as well as its shareholders and the communities the Bank serves. Consistent with this duty, the Board continues to review the Filings by the Shareholder Group carefully and objectively in the same manner it would evaluate input from any shareholder or third party. As fiduciaries, the Board remains open to any and all proposals to maximize value. The Board has retained Keefe, Bruyette & Woods, Inc., a leading investment bank specializing exclusively in the financial sector, to advise the Board with respect to any proposals. The Board has also authorized KBW to communicate directly with the Shareholder Group about the Filings." Shareholders are not required to take any action at this time.

08:08 EST Metracrine expects cash to fund operating plan through 2023 - Cash, cash equivalents and short-term investments were an estimated $76.4 million as of December 31, 2021. Metacrine believes it has sufficient capital to fund its current operating plan through 2023.

08:07 EST Metracrine implements restructuring plan including 50% staff reduction - To support ongoing clinical development of MET642 in IBD, the Company is implementing a restructuring plan to significantly reduce expenses associated with its operations in order to preserve cash. The restructuring includes a staff reduction of approximately 50% primarily consisting of the Company's research organization. As a result, Metacrine has also discontinued preclinical development of its hydroxysteroid dehydrogenase program. "We are now focusing all of our development effort on bringing expanded therapeutic options to people living with IBD," said Preston Klassen, M.D., MHS, CEO, Metacrine. "We have generated preclinical data that supports moving our MET642 program into clinical testing in IBD during the next few months. The rationale for FXR-based therapies in IBD is anchored on the potential to address multiple aspects of IBD pathogenesis without the immunosuppression inherent to other advanced-line therapies. FXR is highly expressed by intestinal epithelial cells and plays a key role in healthy intestinal function by maintaining the epithelial barrier, reducing bacterial translocation into the intestinal wall and regulating the innate immune response. FXR therapy could bring an oral, once-daily, well-tolerated and non-immunosuppressive medicine to patients. We're also taking restructuring steps to manage our resources and significantly extend our cash runway as we evaluate a range of ways to generate value from our discovery programs, product candidates and financial assets. I am grateful for the dedication of my fellow colleagues to our mission and thank them for their many contributions over the last several years."

08:06 EST Metracrine receives FDA authorization to proceed with Phase 2 trial of MET642 - Metacrine announced that it remains on track to begin a Phase 2 clinical trial in ulcerative colitis. Metacrine has received authorization from the U.S. Food and Drug Administration to proceed with its Phase 2 trial evaluating MET642 in subjects with inflammatory bowel disease and expects to begin the study in the first half of 2022.

08:04 EST GCM Grosvenor raised $1.5B for diverse manager investment mandates in 2021 - GCM Grosvenor announced that it raised $1.5B for diverse manager investment mandates in 2021, bringing its total diverse manager assets under management to approximately $11B as of December 31, 2021. The $1.5B consists of approximately $500M raised for diverse manager mandates in Real Estate and $1B raised for diverse manager mandates in Private Equity, including capital raised for the firm's $770M inaugural Advance Fund, which held its final closing on December 30, 2021. A total of 55 institutional investors made commitments to diverse manager mandates in 2021, 43 of which were new investors to GCM Grosvenor. GCM Grosvenor has invested with diverse managers since 2002.

08:03 EST American Axle announces 2022-2024 new business backlog - AAM's gross new and incremental business backlog launching from 2022 - 2024 is estimated at approximately $700M in future annual sales. AAM expects the launch cadence of the three-year backlog to be approximately $175M in 2022, $325M in 2023 and $200M in 2024. Electrification mix approximates 35% of AAM's new business backlog versus 15% in the prior backlog (2021-2023).

08:02 EST Twitter authorizes $2B accelerated share repurchase agreements - Twitter has entered into accelerated share repurchase agreements with Morgan Stanley and Wells Fargo Bank, National Association - collectively, the dealers - to repurchase $2B of the company's common stock. The ASRs were entered into pursuant to Twitter's recently announced share repurchase program, under which approximately $2B of share repurchase authorization will remain available upon completion of the ASRs. Under the ASRs, Twitter will pre-pay the $2B purchase price to the dealers and will receive an initial delivery of approximately 37.8 million shares of the company's common stock, with any remaining shares expected to be delivered by the end of the company's Q3. The final number of shares to be repurchased will be based on the volume-weighted average price of the company's common stock during the terms of the ASRs less a discount.

07:53 EST Regeneron reports 'encouraging' results from Phase 2 trial of aflibercept 8 mg - Regeneron announced results from its Phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of EYLEA Injection in patients with wet age-related macular degeneration. The results will be presented at the Angiogenesis 2022 annual meeting on Saturday, February 12. As previously announced, more patients treated with aflibercept 8 mg had no retinal fluid at week 16, when the primary efficacy endpoint was assessed. At this timepoint, 43% had no fluid in the macula compared to 26% for EYLEA and 51% had no fluid in the center subfield compared to 34% for EYLEA. At week 16, patients in both treatment groups had received three initial doses, after which dosing was extended to every 12 weeks. In new results presented for the first time, aflibercept 8 mg continued to show numeric improvements in anatomical and vision outcomes compared to EYLEA through 44 weeks. "These Phase 2 data in wet AMD demonstrate the exciting potential for aflibercept 8 mg to maintain dryness and improve vision compared to the standard-of-care EYLEA," said Dr. David Brown, Director of Research at Retina Consultants of Texas. "This is the first time we have seen a promising trend towards sustained improved vision over EYLEA in wet AMD. I look forward to seeing the results of the Phase 3 program investigating extended dosing of aflibercept 8 mg." Eyes treated with aflibercept 8 mg were more likely to be dry in the center subfield on optical coherence tomography compared to EYLEA at every timepoint measured throughout the trial after the initial monthly dosing period.

07:46 EST Goodyear Tire reports Q4 tire unit volumes 48.6M, up 29% y/y - Tire unit volumes totaled 48.6M, up 29% from the prior year's period. Replacement tire unit volume increased 39%, reflecting the addition of Cooper Tire unit volume and market share gains. Original equipment unit volume decreased 1%, reflecting lower vehicle production, which continued to be affected by shortages of components and materials, partially offset by market share gains in the legacy Goodyear business.

07:40 EST Entourage Health appoints George Scorsis as CEO - The Company's board of directors announced that George Scorsis has been appointed to the permanent role of CEO, in addition to his role as Executive Chair of the Board. Serving as the Company's Executive Chair since December 2019, Mr. Scorsis has also held the role of interim CEO of Entourage since January 2021. Mr. Scorsis commented: "I am thrilled to be leading our talented Entourage team into 2022 with a continued drive for strong execution - focused on revenue growth and financial discipline as we look to achieve our profitability goals by the end of 2022. Having recently completed the full integration of a newly acquired accretive genetics business, enhanced our cultivation platform and launched some of the most favoured cannabis products in Canada - I'm proud to confirm we closed out a stellar year with expanded market share and a projected C$54.8 million in record revenue. We are well positioned for another standout year of growth and I look forward to sharing further updates on our progress."

07:36 EST Dominion broadens Net Zero commitments - As one of the nation's leading clean-energy companies, Dominion Energy is broadening efforts to limit greenhouse gas emissions. Building on plans to achieve Net Zero carbon and methane emissions from power generation and natural gas operations by 2050, Dominion Energy will now work to achieve Net Zero for emissions outside of the company's direct operations. These include emissions generated downstream by customers and upstream by suppliers.

07:34 EST GoDaddy announces $3B share repurchase plan, to launch $750M ASR in Q1 - GoDaddy CFO Mark McCaffrey said on Thursday: "We're pleased to announce a $3B share repurchase plan, with the intent to launch a $750M accelerated share repurchase in the first quarter of 2022."

07:27 EST Senseonics receives FDA approval for Eversense E3 CGM System - Senseonics announced the approval of the next-generation Eversense E3 CGM System by the FDA. The Eversense E3, including proprietary sacrificial boronic acid, or SBA, technology to extend longevity to six months, is planned to be available to patients in the U.S. through Ascensia Diabetes Care, Senseonics' global commercial partner, beginning in the Q2 of 2022.

07:25 EST Spectrum announces poziotinib NDA accepted for review by FDA - Spectrum announced that its new drug application, or NDA, for poziotinib has been accepted for review by the FDA.

07:18 EST Cleveland-Cliffs sees FY22 average selling price $1,225 per net ton - Due to the renewal of relevant fixed price sales contracts, and based on the current 2022 futures curve which implies an average hot-rolled coil steel index price of $925 per net ton for the remainder of the year, the company would expect its 2022 average selling price to be approximately $1,225 per net ton. In comparison, in 2021, when the hot-rolled coil steel index price averaged approximately $1,600 per net ton, the company's average selling price was $1,187 per net ton.

07:08 EST Getty Images renews partnership with AFP for video news content - Getty Images and Agence France-Presse - AFP -, a global news agency, renewed their multi-year video partnership. Since 2009, the global visual content companies have worked in partnership to ensure video coverage of global events.

07:05 EST Flowr provides operational update on facilities owned by subsidiary Holigen - The Flowr Corporation provides an operational update at its facilities located in Portugal owned and operated by Flowr's wholly-owned subsidiary, Holigen. Sintra Facility: At the Sintra facility, all capital expenditures have been made and the facility is fully operational. The facility is a 25,000 square foot purpose-built medical cannabis facility that mirrors the technology developed at Flowr's K-1 and Kelowna Research Station located in Kelowna, British Columbia. Holigen expects to receive the Cookies genetics in the first quarter of 2022. Holigen expects to harvest approximately 300 kilograms of medical cannabis in the first quarter of 2022 and over 2,000 kilograms of premium cannabis per year from the Sintra facility. Genetics Portfolio: The Company has successfully exported its flagship high-THC strains - BC Pink Kush, BC Black Cherry and BC Strawnana - from Canada to Portugal. Holigen has established a robust stock of healthy mother plants and has initiated its first harvest. Holigen has initiated the product registration process and will submit for market authorization in Portugal, Germany, UK, and others in the first quarter of this year, and expects to receive approvals in the second half of 2022. Co-Manufacturing Services: After successfully completing validation batches in 2021 and generating approx. EUR 500k in revenue from tolling services last year, the company is now offering these services to additional clients. Holigen expects this to exceed EUR 500,000 per quarter in the second half of 2022. Lab Services: Holigen expects the launch of third-party lab services to result in significant annual revenue.

07:04 EST Genpact raises quarterly dividend 16% to 12.5c per share - Payable on March 23 to shareholders of record as of the close of business on March 10.

06:59 EST Apollo Global reports Q4 AUM $497.6B

06:43 EST Aspen says Aspen University to immediately stop new enrollments in Phoenix - In a regulatory filing yesterday, Aspen Group disclosed that Aspen University, Inc., the company's wholly-owned subsidiary, issued a public statement regarding actions taken by the Arizona Board of Nursing and its proposed probation terms on Aspen University's BSN pre-licensure program in Arizona. The company stated: "Aspen University began the Program in Phoenix nearly three and a half years ago, and our initial cohort graduated in 2020 meeting all Arizona State standards. Throughout the calendar year 2021, as the spread of COVID-19 worsened, Nursing schools were forced into primarily virtual teaching and clinical environments, a less than optimal educational experience. As a result of these challenges, nationwide NCLEX-RN first-time pass rates among all nursing schools dropped from 78.4% in 2020 to 71.9% in 2021. Aspen University's NCLEX-RN first-time pass rates in 2021 were 58%, consequently we failed to meet the minimum 80% standard set by the Arizona Board. Aspen University adopted numerous changes throughout 2021 increasing the Program rigor which are already showing results as we expected. In the first calendar quarter of 2022, as of February 10, 2022, Aspen University's pass rate is 85%. It is our hope that the Arizona Board will recognize our improvements and not choose to diminish our ability to provide a pathway to meet the increasing demand for nurses in Arizona with qualified professionally certified nurses. However, following a request of the Arizona Board, Aspen University has chosen to immediately stop new student enrollments at our main Phoenix campus and HonorHealth campus and not begin our February cohorts at these campuses scheduled to begin on February 15th."

06:31 EST MRC Global elects Robert Wood as next Chairman of the Board - MRC Global announced that its Chairman of the Board, Rhys Best, will retire upon completion of his term as a director at the annual meeting of the company's stockholders scheduled for May 5. The Board of Directors of MRC Global has selected Robert Wood to be its next Chairman of the Board, effective and contingent upon his re-election as a director at the annual meeting.

06:10 EST Fulcrum Therapeutics' treatment of sickle cell disease gets orphan designation - According to a post on the FDA's website, Fulcrum Therapeutics' treatment of sickle cell disease was granted orphan designation. Reference Link

05:25 EST Genentech announces new two-year data from studies of Vabysmo, Susvimo - Genentech, a member of Roche, announced that new two-year data from its Phase III studies of Vabysmo and Susvimo 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022. These longer-term results from the Vabysmo YOSEMITE and RHINE studies in diabetic macular edema, or DME, and the Susvimo Archway study in wet, or neovascular, age-related macular degeneration, or AMD, further reinforce the potential to allow for longer time between treatments and fewer eye injections for people with these conditions, while still achieving and maintaining vision gains seen with previous standard-of-care injections. Wet AMD and DME are two leading causes of vision loss, together affecting nearly 2M people in the U.S., which require treatment with eye injections as often as once a month. In the YOSEMITE and RHINE studies, at least 60% of people eligible for extended dosing with Vabysmo could be treated every four months at two years - a 10 percentage point increase since the primary analysis at one year - while achieving non-inferior vision gains versus aflibercept given every two months. Furthermore, nearly 80% of people eligible for extended dosing with Vabysmo could be treated every three months or longer. In the Archway study, Susvimo allowed 95% of people to go six months between treatments at two years - the fourth complete refill-exchange interval - while maintaining vision outcomes that were non-inferior to monthly ranibizumab injections. Across all three studies, with longer follow-up, Vabysmo and Susvimo continued to be generally well tolerated, with favorable benefit-risk profiles. Safety will continue to be monitored closely in the post-market setting. In the YOSEMITE and RHINE studies, DME patients received Vabysmo, given either every two months or up to every four months using a treat-and-extend approach, or aflibercept given every two months. Two-year results showed Vabysmo patients maintained the vision improvements achieved in the first year and vision gains continued to be non-inferior to those achieved by aflibercept patients. In YOSEMITE, the average vision gains from baseline at two years were +10.7 eye chart letters in both the Vabysmo treat-and-extend and two-month arms, and +11.4 letters in the aflibercept arm. In RHINE, the average vision gains from baseline at two years were +10.1 and +10.9 letters in the Vabysmo treat-and-extend and two-month arms, respectively, and +9.4 letters in the aflibercept arm. Importantly, 60% of Vabysmo treat-and-extend patients in YOSEMITE and 64.5% in RHINE achieved four-month dosing at two years. This is an increase over one-year results, which showed 52.8% of Vabysmo treat-and-extend patients in YOSEMITE and 51% in RHINE achieved four-month dosing. An additional 18.1% of Vabysmo treat-and-extend patients in YOSEMITE and 13.6% in RHINE achieved three-month dosing. Combined, almost 80% of Vabysmo treat-and-extend patients were able to go three months or longer between treatments at the end of the second year. Across study arms, Vabysmo showed consistent two-step or better improvement in diabetic retinopathy according to the Early Treatment Diabetic Retinopathy Study - Diabetic Retinopathy Severity Score (ETDRS-DRSS). At two years, 42.8% of Vabysmo treat-and-extend patients in YOSEMITE and 44.3% in RHINE achieved a two-step or better improvement from baseline. In the two-month Vabysmo arms, 51.4% and 53.5% of patients in YOSEMITE and RHINE, respectively, achieved a two-step or better improvement in diabetic retinopathy severity. Vabysmo given at intervals of up to four months continued to demonstrate greater reductions in central subfield thickness, or CST, compared to aflibercept given every two months in both studies. Safety results were consistent across study arms, with no cases of retinal vasculitis or retinal occlusive events. Wet AMD patients in Archway received either Susvimo refilled every six months or monthly ranibizumab 0.5 mg eye injections. Two-year results showed vision was maintained by Susvimo patients and continued to be non-inferior to that achieved with monthly ranibizumab injections. Susvimo patients averaged -1.1 eye chart letters in visual acuity from baseline at two years, while monthly ranibizumab patients averaged -0.5 letters from baseline. In addition, 95% of Susvimo patients were able to go six months without needing additional treatment in the second, third and fourth refill-exchange intervals. In Archway, Susvimo was generally well tolerated, with a favorable benefit-risk profile. The most common adverse events of special interest were cataract, conjunctival bleb and vitreous hemorrhage. The safety profile of Susvimo in the clinical trial setting is well understood and will continue to be monitored closely. In addition to Archway results, two-year interim data from the ongoing Phase III Portal study will be presented at the Angiogenesis meeting. Portal is an extension study evaluating the long-term safety and efficacy of Susvimo in wet AMD.